All In Biotech

Drug Trial Radar · NCT07397468

To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)

Double-blind, Placebo-controlled, Randomized, Safety and Efficacy Study of JUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI)

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Feb 28, 2026

Primary completion

Jul 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Juvena TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo-controlled, randomized study of 96 days total duration to assess the effect of JUV-161 on muscle disuse atrophy. This will be a multicenter study in New Zealand and will include up to 40 healthy volunteers aged between 40 to 65 years of age. Following the screening period, subjects will be randomized to receive either weekly subcutaneous (SC) injections of one of two doses of JUV-161 or matching placebo for a period of approximately 6 weeks.

Conditions

  • Healthy Volunteers

Interventions

  • JUV-161Drug

    JUV-161 administered subcutaneously at protocol-specified dose levels.

  • PlaceboDrug

    Matched placebo administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: from enrollment through to Day 96
  2. Number of Participants who have Change in Quadriceps Muscle Mass and Volume as assessed by magnetic resonance imaging MRI.Time frame: Change from baseline (pre-treatment) to Day 15 (post-immobilization) and Day 45 (post-treatment)
  3. Number of participants who have Change in lower limb muscle architecture as assessed by MRI.Time frame: Change from baseline (pre-treatment) to Day 15 (post-immobilization) and Day 45 (post-treatment)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Auckland, New Zealand · Recruiting

  • New Zealand Clinical Research

    Christchurch, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.